The companies that survive will look less like pyramids and more like swarms: small, autonomous AI-first pods that move and ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

At a moment where many Navy shipbuilding programs are stalling, the Constellation-class guided missile frigate stands out as the most behind schedule, the most over budget, and the most emblematic of ...

TIOBE Index for December 2025: Top 10 Most Popular Programming Languages Your email has been sent December’s TIOBE Index lands with a quieter top tier but a livelier shuffle just beneath it. The main ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on knowledge of ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Standardizing structural isomeric relationships and evaluating their distribution in chemical space remain significant challenges in cheminformatics. Here, the authors propose a molecular ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...